Our Pricing

Mounjaro Or Wegovy Starter Dose: Which Is Right For You?

Choosing between a mounjaro or wegovy starter dose is one of the most important decisions when beginning GLP-1 weight loss treatment in the UK. Both medications require careful dose titration starting from the lowest therapeutic level, but they differ significantly in active ingredient, dosing schedule, and clinical efficacy. At Cured Pharmacy, our UK-registered prescribers assess your individual health profile to recommend the most appropriate starter dose, with Wegovy available from £124.99 and Mounjaro from £124.99, subject to clinical approval.

Understanding Mounjaro Or Wegovy Starter Dose Protocols

The mounjaro or wegovy starter dose you receive depends on the medication's pharmacokinetic profile and your body's adaptation requirements. Wegovy (semaglutide) begins at 0.25mg weekly for four weeks, allowing gradual GLP-1 receptor engagement whilst minimising gastrointestinal side effects [1]. This conservative initiation has been validated across the STEP clinical trial programme, where participants starting at 0.25mg experienced significantly fewer treatment discontinuations compared to higher initial doses.

Mounjaro (tirzepatide) employs a dual GIP/GLP-1 receptor mechanism, starting at 2.5mg weekly for the first four weeks [2]. Despite the numerically higher dose compared to Wegovy's starter, tirzepatide's unique pharmacology distributes receptor activation across two pathways, which many patients tolerate well during the titration phase. The SURPASS-2 head-to-head trial demonstrated that tirzepatide's starter dose protocol achieved superior glycaemic control and weight reduction compared to semaglutide 1mg, though both medications require gradual escalation to maintenance doses.

Our superintendent pharmacist Tarun Kumar (GPhC 2233073) emphasises that starter dose selection isn't purely about choosing between mounjaro or wegovy starter dose options — it requires comprehensive assessment of your medical history, current medications, and weight loss goals. Patients with significant cardiovascular history may benefit from semaglutide's established CVOT data, whilst those seeking maximum weight reduction potential often respond well to tirzepatide's dual-agonist approach, subject to prescriber approval.

Clinical Efficacy: Mounjaro Or Wegovy Starter Dose Outcomes

When evaluating mounjaro or wegovy starter dose effectiveness, clinical trial data provides crucial guidance. The STEP 1 trial showed that participants starting on Wegovy's 0.25mg dose and titrating to 2.4mg achieved average weight loss of 14.9% over 68 weeks [3]. Importantly, the gradual starter dose escalation protocol resulted in only 4.5% discontinuation due to gastrointestinal adverse events, demonstrating the importance of proper dose initiation.

Tirzepatide's starter dose pathway in the SURMOUNT-1 trial produced even more substantial outcomes, with participants beginning at 2.5mg and escalating to 15mg achieving average weight reduction of 20.9% at 72 weeks [4]. The starter dose phase (weeks 0-4) saw minimal side effect-related discontinuations, suggesting the 2.5mg initiation effectively balances therapeutic activation with tolerability. Across both medications, the starter dose period serves as a critical adaptation window where your body adjusts to GLP-1 receptor modulation.

Real-World Starter Dose Experience

In our clinical practice at Cured Pharmacy, patients frequently ask whether the mounjaro or wegovy starter dose will produce immediate weight loss. Realistic expectations are essential — the starter dose phase primarily focuses on physiological adaptation rather than maximum weight reduction. Most patients experience 2-4% weight loss during the first month on either medication's starter dose, with appetite suppression becoming more noticeable from week 2-3 onwards. The therapeutic effect amplifies significantly as you progress through dose escalation to maintenance levels, which is why adherence to the prescribed titration schedule is crucial for long-term success.

Mounjaro Or Wegovy Starter Dose: Side Effect Profiles

The mounjaro or wegovy starter dose you select influences your initial side effect experience, though both medications share a common GLP-1-mediated adverse event profile. Nausea affects approximately 20-25% of patients during the Wegovy 0.25mg starter phase, typically resolving within 2-3 weeks as tachyphylaxis develops [1]. Diarrhoea, constipation, and abdominal discomfort occur less frequently but may persist if dose escalation proceeds too rapidly without adequate adaptation time.

Mounjaro's 2.5mg starter dose produces similar gastrointestinal effects, with nausea reported in 18-22% of SURPASS trial participants during weeks 1-4 [2]. The dual GIP/GLP-1 mechanism may contribute to slightly different symptom patterns — some patients report less severe nausea but more frequent loose stools compared to semaglutide. Crucially, serious adverse events remain rare with both medications' starter doses when prescribed appropriately, though all patients require monitoring for pancreatitis symptoms, gallbladder complications, and hypoglycaemia if taking concurrent diabetes medications.

Our clinical team advises specific starter dose management strategies to minimise side effects: taking injections in the evening, eating smaller frequent meals, avoiding high-fat foods during weeks 1-4, and maintaining adequate hydration. If you experience persistent vomiting, severe abdominal pain, or signs of acute pancreatitis, discontinue the medication immediately and contact your prescriber. The mounjaro or wegovy starter dose phase should be uncomfortable but tolerable — severe symptoms warrant clinical review before proceeding with dose escalation.

Cost Comparison: Mounjaro Or Wegovy Starter Dose Pricing

Understanding the financial commitment for mounjaro or wegovy starter dose treatment helps patients plan their weight loss journey effectively. At Cured Pharmacy, Wegovy starter dose pens (0.25mg and 0.5mg) are available from £124.99, representing competitive UK pricing for pharmaceutical-grade semaglutide. The complete titration pathway to maintenance dose (2.4mg) typically requires 16-20 weeks, with monthly costs varying as you progress through dose levels.

Mounjaro starter dose treatment begins at £124.99, reflecting tirzepatide's more complex manufacturing process and dual-receptor mechanism. Whilst the initial outlay is higher than Wegovy, many patients find the superior weight loss outcomes justify the additional cost, particularly if previous GLP-1 monotherapy proved insufficient. Both medications qualify for our £20 discount on first orders using code Weightlossnew, and all pricing includes free online prescriber assessment by our UK-registered clinical team.

When calculating total treatment cost, consider that the mounjaro or wegovy starter dose represents only the first month of a long-term weight management programme. Most patients require 12-18 months of continuous treatment to achieve and consolidate their target weight loss, with ongoing maintenance therapy often recommended to prevent weight regain. Our transparent upfront pricing model ensures you know exact costs before completing the clinical questionnaire, eliminating the hidden fees common at other UK pharmacies.

Insurance and NHS Availability

NHS prescribing of mounjaro or wegovy starter dose treatments remains highly restricted, limited to specialist weight management services with strict BMI and comorbidity criteria. Current NICE guidance permits NHS-funded semaglutide only for patients with BMI ≥35 plus weight-related complications, or BMI ≥30 with recent diabetes diagnosis. Mounjaro has even more limited NHS access, available primarily through specialist endocrinology services. Most UK patients seeking timely access to either medication opt for private prescription through registered online pharmacies like Cured Pharmacy, where clinical assessment typically completes within 24 hours.

How To Choose Between Mounjaro Or Wegovy Starter Dose

Selecting the optimal mounjaro or wegovy starter dose requires evaluating several clinical and practical factors with your prescriber. Patients with established type 2 diabetes often achieve better glycaemic outcomes with Mounjaro's dual-agonist mechanism, as demonstrated in SURPASS-2 where tirzepatide reduced HbA1c by 2.24% versus 1.86% for semaglutide [2]. However, Wegovy's extensive cardiovascular outcomes data makes it preferable for patients with significant heart disease history, following the SELECT trial's demonstration of 20% reduction in major adverse cardiovascular events.

Weight loss goals also inform the mounjaro or wegovy starter dose decision. If you're targeting 15-20% body weight reduction, tirzepatide's superior efficacy profile (20.9% average loss in SURMOUNT-1 versus 14.9% in STEP 1) may justify the higher cost [3][4]. Conversely, patients seeking moderate weight loss of 10-15% often achieve excellent results with Wegovy whilst benefiting from lower treatment costs and broader prescriber familiarity with semaglutide dosing protocols.

Practical considerations matter too — Wegovy's lower starter dose may suit patients particularly concerned about side effects or those with previous GLP-1 intolerance. Mounjaro's once-weekly injection schedule matches Wegovy, but the pen device design differs slightly, which some patients find more or less comfortable. Our online assessment captures all these factors, enabling our prescribers to recommend the mounjaro or wegovy starter dose most aligned with your individual circumstances, subject to clinical approval.

Getting Your Mounjaro Or Wegovy Starter Dose From Cured Pharmacy

Accessing your mounjaro or wegovy starter dose through Cured Pharmacy combines clinical rigour with convenient online service. Our process begins with a comprehensive medical questionnaire covering your weight history, previous diet attempts, current medications, and relevant health conditions. This assessment takes under 3 minutes but provides our UK-registered prescribers with essential information to determine suitability for GLP-1 therapy and recommend the appropriate starter dose medication.

Once approved, your prescription is dispensed from our GPhC-registered pharmacy (9012511) using genuine UK-licensed medicines sourced directly from manufacturers. We offer next-day delivery in discreet packaging, ensuring your mounjaro or wegovy starter dose arrives promptly without revealing contents. Each shipment includes comprehensive patient information leaflets, injection technique guidance, and direct contact details for our clinical team should questions arise during your starter dose phase.

Ongoing support distinguishes Cured Pharmacy from other online providers. As you complete your four-week starter dose period, our prescribers proactively contact you to assess tolerability, review weight loss progress, and arrange the next dose escalation step. This continuity of care ensures safe titration through the complete dosing schedule, optimising both efficacy and safety throughout your weight loss journey. All prescription renewals require clinical review, maintaining the rigorous standards expected of UK-registered pharmacy services.

Next Steps

Ready to begin your mounjaro or wegovy starter dose treatment? Click the 'Start Assessment' button to complete our confidential medical questionnaire. Our prescribers review submissions within 24 hours, and approved prescriptions typically dispatch the same working day for next-day delivery. Remember to use code Weightlossnew for £20 off your first order, and contact our team on (+44) 116 4646009 if you have questions about which starter dose option suits your needs best.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
2. Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. [accessed 15 August 2026]
3. Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083-2091. [accessed 15 August 2026]
4. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 15 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.